[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"syphilis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:syphilis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,49,76,105,132,165,195,222,246,275,308,333,361,381,404,431,453,473,501],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100572833","phase-4-doxycycline-prophylaxis-for-prevention-of-sexually-transmitted-infections-100572833",false,"NCT06738407","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States","Inclusion Criteria:\n\n* Age 13-29 years, inclusive;\n* Self-reports GC, CT, and\u002For early syphilis diagnosis in the 12 months prior to screening;\n* Self-reports condomless (oral, vaginal, and\u002For anal) intercourse at least once in the 30 days prior to screening\n* Is at least 45 kilograms (99.2 pounds) in weight\n* Fluent in English (able to read, speak, and understand English);\n* Willing to undergo all required study procedures; and\n* Willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Is male;\n* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;\n* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;\n* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;\n* Current or planned use of doxycycline for a prolonged period (\\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;\n* Prolonged antibiotic use (\\> 2 weeks) within the last 30 days prior to enrollment;\n* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;\n* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or\n* Any other medical condition, medical\u002Fbehavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)\u002FInvestigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results.","FEMALE","13 Years","29 Years",{"count":20,"type":21},760,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.",[27,28,29,30],"Gonorrhea","Chlamydia","Syphilis","Sexually Transmitted Infections (STIs)",[32,33,34,35],"Sexually Transmitted Infections","STIs","Doxycycline Prophylaxis","Doxycycline","RECRUITING","2026-05-12",{"date":39,"type":40},"2026-05-15","ACTUAL",{"date":42,"type":40},"2026-02-27",{"date":44,"type":21},"2028-06-15",{"name":46,"class":47},"Westat","OTHER",13,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100565663","offering-routine-and-rapid-point-of-care-poc-syphilis-testing-in-pregnant-patients-presenting-to-the-emergency-department-100565663","NCT06645106","Offering Routine and Rapid Point of Care (POC) Syphilis Testing in Pregnant Patients Presenting to the Emergency Department","Inclusion Criteria:\n\n* Pregnant individuals that are seeking care at University of Texas, Memorial Herman and Lyndon B Johnson sites ED or obstetrical triage units.\n* No Prenatal care during index pregnancy\n* No documented syphilis result during the index pregnancy\n\nExclusion Criteria:\n\n* Pregnant individuals with documented care and syphilis results in the index pregnancy for specific trimester as mandated by Texas law","18 Years","50 Years",{"count":58,"type":21},1500,[60],"NA","The purpose of this study is to offer routine lab-based and rapid point of care (POC) syphilis diagnostic testing in the emergency department (ED) and obstetrical (OB) triage , thereby increasing screening and treatment initiation for pregnant patients without prenatal care or with no documented syphilis results during the index pregnancy in other to increase rates of full treatment to determine if the implementation of a robust linkage to care program for pregnant patients with positive rapid POC results will more likely result in complete treatment for all stages of syphilis and adherence to recommended maternal and newborn longitudinal follow up and to assess factors that contribute to treatment completion after implementation of the intervention will also be analyzed to tailor efforts targeting social and healthcare navigation factors that affect health equity; including poverty, insurance, health literacy and others.",[29],[64,65],"syphilis diagnostic testing","pregnancy","2026-05-04",{"date":68,"type":40},"2026-05-06",{"date":70,"type":40},"2025-02-04",{"date":72,"type":21},"2028-02-01",{"name":74,"class":47},"The University of Texas Health Science Center, Houston",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":75},"100549025","a-seek-test-and-treat-intervention-to-reduce-chlamydia-trachomatis-disparities-100549025","NCT06428643","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities in Black Youth Living in the Deep South","Inclusion Criteria:\n\n* Identifies as African American or Black\n* 15-26 years of age\n* Lives or spends most of their time in Orleans Parish\n* Had vaginal sex at least once\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Unable to speak or understand English\n* Previously enrolled in the study\n* Known to be pregnant\n* Known HIV positive status",true,"ALL","15 Years","26 Years",{"count":88,"type":21},2322,[60],"This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.",[28,27,92,29],"Hiv",[94,95],"Screening","Expedited Treatment","2026-04-30",{"date":98,"type":40},"2026-05-05",{"date":100,"type":40},"2025-08-14",{"date":102,"type":21},"2029-09-01",{"name":104,"class":47},"Tulane University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":75},"100436045","phase-3-cefixime-clinical-trial-100436045","NCT04958122","Cefixime Clinical Trial","Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis","Inclusion Criteria:\n\n* Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment\n* 18 years of age or older\n* Able to provide informed consent\n* Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load \\\u003C200 copies\u002FmL) or have a CD4 count ≥ 350 cells\u002Fmm3 according to most recent labs before study enrollment\n\nExclusion Criteria:\n\n* Pregnancy or a positive pregnancy test on the day of enrollment\n* Patients showing signs and symptoms of neurosyphilis\n* Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater\n* Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)\n* Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test\n* Self-reported allergy to cephalosporins or penicillin\n* Unwilling or unable to attend follow-up visits",{"count":113,"type":21},400,[115],"PHASE3","This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.",[29,118],"Human Immunodeficiency Virus",[120,121,122,123],"Cefixime","Treponema pallidum","Penicillin","Early Syphilis","2026-04-27",{"date":66,"type":40},{"date":127,"type":40},"2021-06-20",{"date":129,"type":21},"2027-06-30",{"name":131,"class":47},"University of Southern California",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":83,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":150,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":75},"100574980","integrated-care-versus-usual-care-for-opioid-use-disorder-and-infectious-diseases-in-veterans-100574980","NCT06766331","Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder","Inclusion Criteria:\n\n* US Veteran\n* Able to provide written informed consent in English\n* Living in the community (Nassau, Suffolk, Kings, Queens, Bronx, Westchester, Rockland counties, NY)\n* Documented diagnosis of moderate to severe opioid use disorder\n* Seeking care at the Northport VA substance use disorder clinic for opioid use disorder treatment\n* Willing to have HIV, HBV, HCV, or bacterial STI testing to determine negative or positive status\n* Persons who test negative for HIV need to meet CDC PrEP eligibility criteria in the 6 months prior to enrollment\n\nExclusion Criteria:\n\n* Severe medical or psychiatric disability making participation unsafe\n* Unable to provide written consent\n* PrEP exclusion: HIV positive test; HBV positive test",{"count":140,"type":21},60,[60],"Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.",[144,145,146,27,28,29,147,148,149],"Opioid Use Disorder","HIV","Hepatitis C Virus","Sexually Transmitted Infection","Integrated Care","Medications for Opioid Use Disorder",[151,145,152,153],"Hepatitis C","sexually transmitted diseases","Opioid-Related Disorders","NOT_YET_RECRUITING","2026-04-21",{"date":157,"type":40},"2026-04-24",{"date":159,"type":21},"2028-04-03",{"date":161,"type":21},"2029-06-29",{"name":163,"class":164},"VA Office of Research and Development","FED",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":83,"sex":84,"minAge":173,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100632686","evaluation-of-free-sti-testing-pilot-projects-in-lucerne-and-zurich-switzerland-100632686","NCT07516912","Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich","feSTI","Inclusion Criteria:\n\n* taking part in the pilot programmes\n* understand the study information\n* 16 years of age or older\n\nExclusion Criteria:\n\n* not eligible for the pilot programmes\n* not understanding the study information\n* less than 16 years old","16 Years",{"count":175,"type":21},1800,"OBSERVATIONAL","The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.",[179,28,27,29,180],"HIV (Human Immunodeficiency Virus)","HCV",[182,183,145,184,185],"Voluntary counselling and testing","sexually transmitted infections","implementation of free testing","barriers to care","2026-04-02",{"date":188,"type":40},"2026-04-08",{"date":190,"type":21},"2026-04-07",{"date":192,"type":21},"2029-02-28",{"name":194,"class":47},"University of Zurich",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100616026","treponemal-shedding-load-and-viability-in-women-and-men-who-have-sex-with-women-only-with-early-infectious-syphilis-implications-for-transmission-100616026","NCT07300254","Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women-only With Early Infectious Syphilis: Implications for Transmission","Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women Only With Early Infectious Syphilis: Implications for Transmission","SOS Global","Inclusion Criteria:\n\n\\- 1. Any cis-woman, cis-MSW, or nonbinary individuals with a penis who have sex with women only, (who meet all other study criteria) 2. Aged ≥18 years of age, 3. At least one sexual partner in the last 12 months 4. One of either:\n\na. Untreated clinically suspected primary or secondary syphilis. i. Must have rash or lesion(s) clinically suggestive of early infectious syphilis infection.\n\nii. May have positive PCR result, positive Dark-ground Microscopy result, positive syphilis serology or positive point-of-care syphilis test, but these are not necessary at the time of enrolment.\n\nb. Untreated early latent (no clinical signs indicative of primary or secondary syphilis) syphilis with positive syphilis serology or positive point-of-care test, and one or more of the following(11): i. A documented syphilis seroconversion within the prior 12 months. ii. A sustained (longer than 2 weeks) fourfold or greater increase in the titre in the prior 12 months in a person previously treated for syphilis.\n\niii. Unequivocal symptoms of primary or secondary syphilis within the prior 12 months.\n\niv. Contact in the prior 12 months with a sex partner who had untreated primary, secondary, or early latent syphilis.\n\nv. Documented reactive nontreponemal and treponemal tests, and the only possible exposure occurred during the previous 12 months vi. RPR\u002FVDRL titre \\>= 1:64 5. Be willing and able to complete study procedures, including physical examination 6. Receiving syphilis treatment on the day of recruitment 7. Have sufficient language proficiency to understand the requirements of the study 8. Provide informed consent as per individual site's local ethics requirements\n\nExclusion Criteria:\n\n1. Men, transwomen, or other people, with a penis, who have had any sexual contact, including kissing, oral sex or anal sex, with men (or any other individual with a penis) in the previous one year.\n2. Individuals who have received antibiotic treatment within 1 month prior to enrolment, with the EXCEPTION of metronidazole.\n3. Diagnosis of late latent syphilis (\\>1 year) or latent syphilis of unknown duration.",{"count":204,"type":21},480,"How syphilis is transmitted between sexual partners is unclear. Asymptomatic detection i.e. detection of syphilis bacteria (Tp) from anatomical sites without lesions, in patients with syphilis infection, suggests that asymptomatic transmission from these sites may play a role. However, no existing studies have established whether the syphilis bacteria (Tp) detected was viable. This means it is not known if the bacteria at this anatomical site is alive and therefore able to transmit the infection. Further, studies have focused mostly on men who have sex with men, resulting in a lack of evidence regarding anal shedding in men-who-have-sex-with-women only and women (regardless of sexual behaviour), and no data on asymptomatic vaginal shedding in women. This study will explore:\n\n1. Patterns of Tp detection in women and men-who-have-sex-with-women only.\n2. Whether detected Tp from each asymptomatic anatomical sites is viable\n3. Duration of Tp detection and viability (alive and transmissible bacteria). Patients presenting to a participating sexual health service (overseas only) for management of suspected\u002Fconfirmed early infectious syphilis will be eligible. During the routine clinical examination, participants will have additional oral and anal swabs, urine, vaginal swab (where relevant), penile skin swab (where relevant) and blood sample collected, in addition to the routine samples taken from the same sites and routine serology collected when syphilis is diagnosed.",[29],[208,209,210,211],"syphilis","sexual health","syphilis transmission","asymptomatic shedding","2026-04-01",{"date":214,"type":40},"2026-04-03",{"date":216,"type":40},"2025-12-02",{"date":218,"type":21},"2028-12-31",{"name":220,"class":47},"Monash University",9,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":83,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":75},"100631418","doxi-rio-study-on-the-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-rio-de-janeiro-100631418","NCT07500415","Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro","Doxi-Rio: Pilot Implementation of Post-exposure Prophylaxis for Sexually Transmitted Infections With Doxycycline in Rio de Janeiro, Brazil","Inclusion Criteria:\n\n* Individuals assigned male at birth (cisgender or transgender men), transgender women, or travestis who have sex with men\n* Age ≥18 years\n* Living with HIV or currently using HIV pre-exposure prophylaxis (PrEP) for at least 6 months\n* History of at least one bacterial sexually transmitted infection (chlamydia, gonorrhea, or syphilis) in the past 12 months (laboratory-confirmed or self-reported)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to doxycycline or other tetracycline-class antibiotics\n* Current use of medications that may significantly interact with doxycycline or are contraindicated, including systemic retinoids, barbiturates, carbamazepine, or phenytoin",{"count":230,"type":21},200,[60],"The goal of this clinical trial is to learn if doxycycline post-exposure prophylaxis (doxy-PEP) can help prevent bacterial sexually transmitted infections (STIs) among sexual and gender minorities in Rio de Janeiro, Brazil, including men who have sex with men, transgender women, and travestis who are living with HIV or using HIV pre-exposure prophylaxis (PrEP). Bacterial STIs such as syphilis, gonorrhea, and chlamydia remain common in these populations, even with existing prevention strategies.\n\nThis study aims to answer the following questions: whether doxy-PEP can reduce the number of new STIs, whether it is safe and well tolerated, whether participants use it as recommended, and whether its use may contribute to antibiotic resistance or changes in the body's natural bacteria. Doxy-PEP involves taking a dose of doxycycline, an antibiotic, shortly after sexual activity to reduce the risk of acquiring STIs.\n\nParticipants will first receive information and counseling about doxy-PEP, including its possible benefits and risks, and will then choose whether or not to use this prevention strategy. Those who choose to use doxy-PEP will take doxycycline after sex as instructed and will be followed for up to 48 weeks, with clinic visits approximately every three months. During these visits, participants will be tested for STIs, monitored for side effects, and asked about medication use, sexual health, and overall well-being.\n\nResearchers will collect information on new STI diagnoses, safety, and how consistently participants use doxy-PEP. The study will also explore participants' experiences and perceptions of this strategy. The results of this study will help determine whether doxy-PEP is a practical and acceptable approach for STI prevention in Brazil and may inform future public health strategies.",[234,29,27,235,236],"Sexually Transmitted Diseases","Chlamydia Infections","HIV Infections","2026-03-24",{"date":239,"type":40},"2026-03-30",{"date":241,"type":40},"2025-10-28",{"date":243,"type":21},"2028-05",{"name":245,"class":47},"Oswaldo Cruz Foundation",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":83,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":256,"conditions":257,"keywords":261,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":274},"100606069","clinical-performance-evaluation-of-magia-ivd-md-multiplex-testing-hivhbvhcvsyphilis-100606069","NCT07170748","Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV\u002FHBV\u002FHCV\u002FSyphilis)","Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa","MAGICS IBCS","Inclusion Criteria:\n\n* Provide informed consent for participation in this study.\n* Patient sample must meet at least one of the criteria below:\n\n  1\\. Positive samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* HIV-1 Ab positive\n* HIV-2 Ab positive\n* HCV-Ab positive\n* HBsAg positive\n* Positive for at least TPHA, with those positive for both TPHA and VDRL ideally included 2. Negative samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* Blood donors\n* Hospitalized patients or individuals coming to the clinic\n* Vulnerable populations (such as: drug users, prison population, ...) 3. Negative samples (serum or plasma) containing potential interfering substances from individuals who meet at least one of the following conditions:\n* Being a pregnant woman\n* Infected with at least one of the following viruses or bacteria: hepatitis A virus (HAV), hepatitis E virus (HEV), tuberculosis (TB), gonorrhoea, chlamydia, influenza virus, Covid-19\n* Presenting any of the following criteria:\n\n  * High IgG levels\n  * High rheumatoid factor (\\>15 IU\u002FmL)\n  * High cholesterol levels (\\>0.24 md\u002FdL)\n  * High bilirubin levels (\\>0.25 mg\u002FmL)\n  * High triglyceride levels (\\>500 mg\u002FdL)\n  * Diagnosis of cancer\n\nExclusion Criteria:\n\n* Samples from patients below 18 years of age",{"count":255,"type":21},2950,"Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.",[258,145,259,180,29,260],"Multiplex Testing of HIV, HBV, HCV and Syphilis","HBV","Point of Care Testing",[262,145,259,180,29,263],"point of care test","multiplex testing","2026-01-30",{"date":266,"type":40},"2026-02-02",{"date":268,"type":40},"2025-07-29",{"date":270,"type":21},"2026-04",{"name":272,"class":273},"MagIA Diagnostics","INDUSTRY",2,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":83,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":283,"targetDuration":285,"studyType":176,"phases":4,"briefSummary":286,"conditions":287,"keywords":295,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100622850","magia-h3s-point-of-care-test-performance-for-hiv-hbv-hcv-and-syphilis-screening-in-pregnant-women-in-dr-congo-100622850","NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.",{"count":284,"type":21},7500,"12 Months","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[288,289,290,29,291,292,293,294],"HIV - Human Immunodeficiency Virus","HBV (Hepatitis B Virus)","Hepatitis C Virus (HCV)","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B",[296,297,298],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","2026-01-28",{"date":301,"type":40},"2026-02-05",{"date":303,"type":21},"2026-03-01",{"date":305,"type":21},"2027-12-21",{"name":307,"class":47},"Gardiens de Vies",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":83,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":75},"100617366","rapid-hiv-hep-c-and-syphilis-screening-in-a-rural-street-medicine-clinic-100617366","NCT07317687","Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","Rapid HIV, Hepatitis C, and Syphilis Screening in a Rural Street Medicine Clinic in West Virginia","Inclusion Criteria:\n\n* Patients of the WVU Medicine Street Medicine team\n\nExclusion Criteria:\n\n* Patients under the age of 18",{"count":230,"type":21},"West Virginia faces rising rates of HIV, hepatitis, and syphilis, particularly among individuals experiencing homelessness, substance use, and mental health challenges. Traditional blood-draw testing for these infections is often hindered by mistrust, logistical barriers, and delays in results. This study, conducted by the West Virginia University (WVU) Street Medicine program, evaluates a rapid, point-of-care fingerstick test for HIV, Hepatitis C, and syphilis that provides results within 10-20 minutes during mobile clinic visits. Participants may choose rapid testing, traditional blood draw (which also includes Hepatitis B screening), or decline testing. All participants will be invited to complete a brief survey about the experiences with screening methods. The goal is to assess whether rapid testing improves screening uptake, linkage to care, and patient satisfaction, ultimately reducing barriers and disease burden in high-risk populations.",[318,319,29,320],"HIV Testing","HEPATITIS C (HCV)","Hepatitis B Virus (HBV)",[322,323],"Street Medicine","Rapid Fingerstick Testing","2026-01-15",{"date":326,"type":40},"2026-01-20",{"date":328,"type":21},"2026-01",{"date":330,"type":21},"2028-01",{"name":332,"class":47},"West Virginia University",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":83,"sex":84,"minAge":173,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":75},"100561188","a-cross-sectional-investigational-study-to-evaluate-the-sensitivity-specificity-and-utility-of-the-medmira-inc-multiplo-complete-syphilis-tpntp-antibody-test-poct-to-diagnose-infectious-syphilis-in-participants-attending-the-sexual-health-clinic-in-ottawa-ontario-100561188","NCT06586905","A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the MedMira Inc. Multiplo® Complete Syphilis (TP\u002FnTP) Antibody Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Sexual Health Clinic in Ottawa, Ontario.","A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the MedMira Inc. Multiplo® Complete Syphilis (TP\u002FnTP) Antibody Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Sexual Health Clinic in Ottawa, Ontario. The MedMira Inc. Multiplo® Complete Syphilis (TP\u002FnTP) Antibody Test is Authorized for Investigational Use.","Inclusion Criteria:\n\n* Individuals attending the Clinic for routine sexual health care and requiring syphilis testing as part of this care, who are able to provide informed consent and are a minimum 16 years of age are eligible for this study. This includes patients attending the Clinic for follow-up appointments following diagnosis with syphilis infection. Those who have had other STIs in the past, or being suspected of having other STIs, are not excluded as long as testing for syphilis is part of the care provided to them. Once it has been determined that the exclusion criteria does not apply to a patient, the recruitment of participants will be offered without other pre-selection criteria unless there may be other unforeseeable circumstances arising, such as shortage of Clinic staff or large numbers of patients in attendance.\n\nExclusion Criteria:\n\n* Those who, at the discretion of the HCPs\u002Fresearch co-ordinator, appear intoxicated and\u002For with extreme distress, or confused, will be excluded from this research because they would not be able to provide informed consent to participate, as well as those below the age of 16 years.",{"count":341,"type":21},1300,[60],"Due to the recent resurgence of infectious syphilis in Canada and the changing epidemiology of the disease to involve heterosexuals and females of child bearing age leading to a record number of congenital syphilis cases and stillbirths, the demand of a rapid test such as POCT that can be used at the place and time that front-line public health workers meet the at risk population is getting louder. Indeed during a number of federal, provincial and territorial meetings on the control of syphilis outbreaks in Canada, requests for POCT to detect syphilis infections have repeatedly come up. However, before a POCT can be widely used, research to find out if it is accurate and reliable is necessary. This study is designed to test the performance of the MedMira Inc. Multiplo® Complete Syphilis (TP\u002FnTP) Antibody Test (POCT) (MedMira Inc., Halifax, Nova Scotia) in an urban clinic (Sexual Health Clinic) in Ottawa, Ontario, Canada and compare its performance in parallel with the usual testing method (the gold standard, i.e. conventional syphilis serology testing).",[29,345],"Treponema Pallidum",[29,347,348,349,121,350,351],"TP\u002FnTP","Multiplo Complete Syphilis (TP\u002FnTP) Antibody Test","MedMira","rapid test","point of care","2025-11-17",{"date":354,"type":40},"2025-11-18",{"date":356,"type":40},"2024-08-26",{"date":358,"type":21},"2026-07-31",{"name":360,"class":273},"MedMira Laboratories Inc.",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":84,"minAge":4,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":221},"100522425","modernizing-perinatal-syphilis-testing-100522425","NCT06082453","Modernizing Perinatal Syphilis Testing","Inclusion Criteria:\n\n* Maternal diagnosis of syphilis by 2021 CDC STI guidelines, irrespective of treatment status; AND viable pregnancy with gestational age ≥ 12 weeks OR postpartum ≤ 96 hours from delivery OR Neonates of pregnancies affected by syphilis ≤ 72 hours of birth\n* Individuals (men and non-pregnant) with syphilis in Harris Health clinic with syphilis\n\nExclusion Criteria:\n\n* Pregnant individuals and neonates who do not meet the criteria of syphilis (false positive)\n* Planning to move outside of study prior to ND testing","45 Years",{"count":369,"type":21},924,[60],"The purpose of this study is to determine the testing performance of real-time quantitative polymerase chain reaction and transcription mediated amplification by comparing test performance of these novel molecular tests to current 2021 CDC CS guidelines for maternal\u002Fneonatal dyads at risk for syphilis infection and to determine whether CS is associated with adverse neurodevelopmental outcomes.",[29],"2025-10-30",{"date":375,"type":40},"2025-11-03",{"date":377,"type":40},"2023-05-02",{"date":379,"type":21},"2027-11-30",{"name":74,"class":47},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":84,"minAge":388,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":75},"100606300","congenital-and-maternal-point-of-care-rapid-testing-for-syphilis-study-uganda-100606300","NCT07173764","Congenital and Maternal Point of Care Rapid Testing for Syphilis Study, Uganda","COMPARTS","Inclusion Criteria:\n\n* Mothers delivering at Kawempe National Referral Hospital with a positive syphilis rapid diagnostic test during their current pregnancy.\n\nExclusion Criteria:\n\n* Mothers who are unable to give written informed consent.\n* Mothers with evidence of neurological symptoms compatible with neurological syphilis.\n* Mothers who are aged less than 14 years. Emancipated and mature minors are allowed to consent for research per Ugandan law.11\n* Mothers, who in the view of the study team, are unable to adhere to required study procedures","14 Years",{"count":390,"type":21},24,"Syphilis is an infection which affects about 1 in 25 pregnant women in Uganda. If the infection is not diagnosed and treated this can be a risk to the mother and unborn baby's health. This study aims to see whether a new test for syphilis infection in mothers and babies which can give a result in 10 minutes is as good as the standard tests that are done in the laboratory and take hours or days to provide results.",[29,393],"Syphilis, Congenital",[208,262],"2025-09-08",{"date":397,"type":40},"2025-09-15",{"date":399,"type":21},"2025-09",{"date":401,"type":21},"2025-12",{"name":403,"class":47},"St George's, University of London",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":83,"sex":84,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":75},"100579846","the-feasibility-of-implementing-syphilis-point-of-care-testing-into-a-prenatal-clinic-for-people-facing-barriers-to-care-100579846","NCT06829602","The Feasibility of Implementing Syphilis Point-of-care Testing Into a Prenatal Clinic for People Facing Barriers to Care","PREnatal Syphilis Point-of-care ScreenING in an Urban Low-barrier Clinic: A Prospective Single Arm Feasibility Trial","PRESSING","1. Pregnant people\n\n   Inclusion Criteria:\n   * Pregnant clients with at least one risk factor for syphilis infection:\n\n     1. Substance use or accessed addiction services in the past 1 year\n     2. Unstable housing in the past 1 year\n     3. Multiple sexual partners in the past 1 year\n     4. History of a sexually transmitted or blood-borne infection (STBBI)\n     5. Late to prenatal care (initial prenatal visit \\>20 weeks)\n   * Eligible for syphilis screening at that clinic visit, as per Public Health guidelines\n\n   Exclusion Criteria:\n   * Previous syphilis diagnosis\n   * Not competent to consent to study participation\n2. Sexual partners\n\nInclusion Criteria:\n\n* Sexual partners of pregnant clients who are newly diagnosed with syphilis\n* Physically present in the clinic\n\nExclusion Criteria:\n\n* Previous syphilis diagnosis\n* Not competent to consent to study participation","49 Years",{"count":414,"type":21},77,[60],"The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV.\n\nThe main questions the study aims to answer are:\n\n* How often do pregnant people at risk of syphilis agree to the rapid test?\n* How well do healthcare providers perform the rapid test?\n* Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners?\n\nParticipants will:\n\n* Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and\n* Share information about their health, pregnancy, and syphilis treatment (if applicable).",[29],[208,65,419,420,421],"access to care","acceptability","point-of-care test","2025-07-03",{"date":424,"type":40},"2025-07-06",{"date":426,"type":40},"2025-06-25",{"date":428,"type":21},"2026-05",{"name":430,"class":47},"McMaster University",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":84,"minAge":55,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":75},"100568623","phase-2-daily-doxycycline-for-early-syphillis-100568623","NCT06683638","Daily Doxycycline for Early Syphillis","Inclusion Criteria:\n\nClinical diagnosis of syphilis (primary or secondary) or laboratory-confirmed early latent syphilis. Specifically: This will include persons meeting any one of the following criteria:\n\n1. Clinical diagnosis of primary syphilis (based on the presence of a chancre) and either a positive qualitative RPR in the absence of a prior positive RPR on their most recent serological test for syphilis or a positive darkfield microscope exam of material taken from a chancre, OR\n2. Clinical diagnosis of secondary syphilis with a positive qualitative RPR in the absence of a prior positive RPR on their most recent serological test for syphilis, OR\n3. A laboratory-confirmed diagnosis of early latent syphilis within one month (i.e. \\\u003C31 days prior).\n\nExclusion Criteria:\n\n1. age under 18\n2. persons with evidence of neurosyphilis (including ocular and otic syphilis) or tertiary syphilis\n3. persons who are unable to give informed consent\n4. persons deemed by the study investigators to be unable to complete study follow-up visits\n5. persons with an allergy to doxycycline\n6. pregnant persons\n7. persons with HIV who report that they are off antiretroviral medication or that they are not virologically suppressed\n8. persons with other known forms of immunosuppression (e.g., persons taking systemic immunosuppressant drugs, persons with primary immunodeficiencies)\n9. persons taking medications that would interact with doxycycline\n10. persons whose initial RPR is lower than 1:4\n11. persons currently prescribed doxy PEP\n12. breastfeeding persons\n\nPersons whose initial laboratory serological tests do not confirm the diagnosis of syphilis with an RPR of 1:4 or higher will be informed that they do not meet study criteria and advised to discontinue doxycycline 200mg once daily. Their subsequent treatment will be based on the judgement of non-research, clinical staff in the clinic and reflect shared decision making between clinical providers and their patient.",{"count":438,"type":21},15,[440],"PHASE2","The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study aims to answer is:\n\nIs doxycycline taken as a single daily dose of 200mg for 14 days an effective treatment for early syphilis based on a combined outcome of clinical improvement and blood test improvement?\n\nParticipants will:\n\n1. Take doxycycline 200mg daily for 14 days\n2. Submit oral and rectal swabs that test for syphilis bacteria every other day for 2 weeks, returned by mail\n3. Complete 2 brief online surveys over the first 2 weeks\n4. Return to the clinic for an interview and blood draw every 3 months for a maximum of 3 study visits, including the first visit\n\nThe investigators will compare the percentage of participants in the study who have response to treatment by 6 months to that of persons who have received standard (CDC-recommended) regimens. To do this, the investigators will calculate response percentage estimates following a shot of long-acting penicillin or 14 days of doxycycline 100mg twice daily from 60-person samples from the sexual health program's records.",[29],[208,444],"doxycycline","2025-06-18",{"date":426,"type":40},{"date":448,"type":40},"2025-03-03",{"date":450,"type":21},"2026-06-26",{"name":452,"class":47},"University of Washington",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100589331","validation-of-self-testing-using-the-insti-multiplex-hiv12-syphilis-antibody-test-100589331","NCT06953024","Validation of Self Testing Using the INSTI Multiplex HIV1\u002F2 Syphilis Antibody Test","Branch #1: Participants known to have an HIV infection - Inclusion criteria:\n\n• Previously documented positive HIV serology\n\nBranch #2: Participants known to have a history of syphilis infection - Inclusion criteria:\n\n• Documented positive syphilis serology\n\nBranch #3: Participants with no known HIV or syphilis infections - Inclusion criteria:\n\n• No documented positive HIV or syphilis serology\n\nExclusion criteria:\n\nUnable to speak and understand English",{"count":460,"type":21},120,[60],"This study aims to validate the percent agreement of the INSTI Multiplex Human Immunodeficiency (HIV) 1\u002F2 syphilis antibody (Ab) test (INSTI POCT) when used as a self-test by patients compared to conventional serologic testing.",[92,29],"2025-04-23",{"date":466,"type":40},"2025-05-01",{"date":468,"type":21},"2025-06",{"date":470,"type":21},"2026-12",{"name":472,"class":47},"Nova Scotia Health Authority",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":83,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":274},"100512384","the-triple-elimination-model-of-mother-to-child-transmission-program-tri-mom-100512384","NCT05951751","The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)","Integrated Antenatal Screening for HIV, Syphilis, and Hepatitis B Virus (HBV) in Pregnant Women in Burkina Faso and The Gambia","TRI-MOM","Inclusion Criteria:\n\n* Women attending a postnatal visit in one of the selected maternities (no maternal age limit)\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Unable to provide consent",{"count":482,"type":21},2800,[60],"The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia.\n\nThe TRI-MOM program has two components:\n\n1. an \"intervention\" component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT.\n2. an \"evaluation\" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.",[92,29,259],[487,488,145,489,29,490,65],"maternal health","child health","Hepatitis B","prevention and control","2024-06-17",{"date":493,"type":40},"2024-06-20",{"date":495,"type":40},"2024-03-18",{"date":497,"type":21},"2025-05",{"name":499,"class":500},"Institut de Recherche pour le Developpement","OTHER_GOV",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":84,"minAge":55,"maxAge":509,"enrollmentInfo":510,"targetDuration":512,"studyType":176,"phases":4,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":75},"100464312","vienna-hiv-infection-via-sex-study-100464312","NCT05326061","Vienna HIV Infection Via Sex Study","Characterization of Patients at High Risk for the Acquisition of Sexually Transmitted Infection With the Human Immunodeficiency Virus (HIV) - a Clinical Study","HIVEX","Inclusion Criteria:\n\n1. High risk for acquiring HIV defined as followed: HIV-negative MSM and transgender individuals who (i) do not use condoms consistently with casual partners and\u002For with HIV-positive partners who are not on treatment and\u002For (ii) recently acquired an STI and\u002For (iii) recently used PEP and\u002For (iv) frequently engage in 'chemsex'.\n2. Age \\>18 years and \\\u003C100 years.\n3. Written informed consent for this registry study.\n\nExclusion Criteria:\n\n1\\. Withdrawal of the written informed consent.","100 Years",{"count":511,"type":21},500,"5 Years","The main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel HIV infections among individuals at high risk for acquiring HIV via sex practices.",[236,515,234,27,28,29],"HIV Pre-Exposure Prophylaxis","2022-04-06",{"date":518,"type":40},"2022-04-13",{"date":520,"type":40},"2020-07-01",{"date":522,"type":21},"2030-12",{"name":524,"class":47},"Medical University of Vienna"]